The Technical Analyst
Gain Therapeutics, Inc. [GANX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Gain Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.94% $3.15
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 51.09 mill |
| EPS: | -1.710 |
| P/E: | -1.840 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 16.22 mill |
| Avg Daily Volume: | 0.161 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.840 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.31x |
| Company: PE -1.840 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.703 (-77.67%) $-2.45 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.81 - 3.49 ( +/- 10.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Mack Gene | Buy | 200 000 | Employee Stock Option (right to buy) |
| 2024-04-05 | Mack Gene | Buy | 0 | |
| 2024-03-28 | Riley Jeffrey Scott | Buy | 30 000 | Common Stock |
| 2024-03-26 | Alder Matthias | Sell | 18 750 | Restricted Stock Units |
| 2024-03-26 | Alder Matthias | Buy | 637 | Common Stock |
| INSIDER POWER |
|---|
| 86.88 |
| Last 62 transactions |
| Buy: 1 996 906 | Sell: 408 942 |
Forecast:
16:00 - $3.15
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.15
Forecast 2: 16:00 - $3.15
Forecast 3: 16:00 - $3.15
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.15 (-0.94% ) |
| Volume | 0.0779 mill |
| Avg. Vol. | 0.161 mill |
| % of Avg. Vol | 48.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GANX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GANX
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Latest Press Releases
2024-04-08 09:25:00 - Press Release
Gain Therapeutics Bolsters Management Team With The Appointment Of Gene Mack As Chief Financial Officer
Bethesda, md., april 08, 2024 (globe newswire) -- gain therapeutics, inc. (nasdaq: ganx) (“gain”, or the “company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of gene mack, mba as its chief financial officer, effective as of april 8, 2024.
2024-04-01 09:25:00 - Press Release
Gain Therapeutics Strengthens Management Team And Appoints Jonas Hannestad, M.d., Ph.d. As Chief Medical Officer
Bethesda, md., april 01, 2024 (globe newswire) -- gain therapeutics, inc. (nasdaq: ganx) (“gain”, or the “company”), a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies, today announces the appointment of jonas hannestad, m.d., ph.d. as its chief medical officer, effective as of march 25, 2024.
2024-03-26 08:00:00 - Press Release
Gain Therapeutics Reports Financial Results For Year End 2023 And Provides Corporate Update
Bethesda, md., march 26, 2024 (globe newswire) -- gain therapeutics, inc. (nasdaq: ganx) (“gain”, or the “company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended december 31, 2023 and provides a corporate update.
2024-03-15 14:30:00 - Press Release
Gain Therapeutics To Present At Public Ventures Discovery Day
Gain therapeutics' former ceo and current board member eric richman to participate in fireside chat hosted by public ventures president lou basenese and aberdeen investment management president jeb terry, sr. gain therapeutics' former ceo and current board member eric richman to participate in fireside chat hosted by public ventures president lou basenese and aberdeen investment management president jeb terry, sr.
2024-03-05 08:00:00 - Press Release
Gain Therapeutics Presents Data At The Ad/pd™ 2024 Conference Demonstrating The Mechanism Of Action Of Gt-02287, Its Clinical Stage Gcase Regulator For The Treatment Of Parkinson's Disease
Data support the ability of gt-02287 to prevent several steps in the disease cascade resulting from gcase misfolding and dysfunction data support the ability of gt-02287 to prevent several steps in the disease cascade resulting from gcase misfolding and dysfunction
Latest News
2024-04-17 10:55:28 - Zacks Investment Research
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2024-04-10 10:36:07 - Zacks Investment Research
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Gain Therapeutics (GANX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2024-03-15 14:30:00 - GlobeNewsWire
Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr. Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr.
2024-01-24 13:01:07 - Zacks Investment Research
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know
Gain Therapeutics, Inc. (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-12-22 17:56:28 - Seeking Alpha
Doubling Down On Gain Therapeutics
The biotech bear market has presented investment opportunities for investors to take meaningful stakes of public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success using its physics-based approach to finding allosteric binding sites on proteins. Recent investment activity and biopharma deals have reduced financial risks for Gain Therapeutics and provided additional valuation comparisons.
2023-12-14 11:17:06 - Zacks Investment Research
Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2023-11-22 13:32:49 - Zacks Investment Research
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.
2023-10-04 08:45:07 - InvestorPlace
Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial.
2023-09-25 16:05:00 - GlobeNewsWire
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023.
2023-09-20 16:05:00 - GlobeNewsWire
Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference
BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference: Drug Discovery for Progressive Central Nervous System Disorders. The event is taking place at the Sheraton Boston in Boston, Massachusetts, between September 26-27, 2023.